Do Fast Track Regulatory Pathways Mean Quicker Reimbursement For Gene Therapies?
The norms on securing market access are being rewritten for cell and gene therapies.
You may also be interested in...
Iris Zemzoum, Novartis Pharma's president for Asia Pacific, Middle East and Africa, outlines how the company is shaping its strategy in the region, which comes with “extremes” in market profiles, via a distinct archetype that factors in commonalities between national healthcare systems. The company is also progressing interesting initiatives in digital therapeutics.
The “chronic disease paradigm” presents a real challenge for companies marketing advanced therapies.
Changes to Canada’s reference pricing system kick in on 1 July and could save billions.